More MS news articles for Oct 2001

Milkhaus Laboratory, Inc. Granted Patent for Treating Diseases Using Low Levels of Antibodies

Thu, Oct 11 9:43 AM EDT

PROVIDENCE, R.I. (BW HealthWire) - Milkhaus Laboratory, Inc, a clinical stage biopharmaceutical company, announced today that it had been granted a patent for the therapeutic use of antibodies at concentrations significantly below those currently employed in the treatment of disease.

The conventional therapeutic application of antibodies involves their use in concentrations which cause a specific antibody to combine with a target antigen to render it inoperable, non-infectious or to neutralize it. More recently, antibodies have been used as vaccines to induce specific immune responses. Antibody therapy is in increasing use today for a variety of indications including immune system deficiency disorders, infections such as hepatitis, and as anti-cancer agents which target specific tumor antigens.

"The implications of this patent are very far reaching. Our work suggests that this invention, one which employs antibodies in low concentrations, involves a molecular signal that ultimately induces a therapeutic response similar to that observed in traditional antibody therapy," said Dr. John McMichael, the Company's founder and CEO. "Our immediate work will be focused on diabetes. However, experience suggests that the technology will be useful in treating a variety of diseases including multiple sclerosis, autism, attention deficit disorder ("ADD"), pulmonary disorders, Alzheimer's Disease and Crohn's Disease," he added.

Milkhaus Laboratory, Inc. is a privately held biopharmaceutical Company focused on the development of therapeutic agents for chronic diseases in man and animals. It has completed successful clinical trials with two of its products: ML-03 in Phase II trials for COPD, bronchitis and cystic fibrosis, and ML-04 in a Phase II evaluation for benign prostatic hyperplasia, or "BPH." Phase II studies of the Company's products for prostatitis and otitis media are scheduled to begin shortly.

©2001 At Home Corporation